[Form 4] Akero Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Akero Therapeutics, Inc. (AKRO) filed a Form 4 reporting that Senior Vice President, Commercial Strategy Patrick Lamy sold 875 common shares on 06/20/2025 at $54.59 per share. The sale was made under the company’s automatic “sell-to-cover” policy to satisfy tax-withholding obligations that arose when restricted stock units vested, and therefore was not discretionary. After the transaction, Lamy continues to own 31,698 shares directly. No derivative securities were involved, and no other insider transactions were disclosed.

Positive

• Insider retains 31,698 shares, indicating continued alignment with shareholders
• Sale executed under an automatic sell-to-cover policy, reducing risk of opportunistic trading perception

Negative

• Insider sale, even if routine, can be viewed as a modest supply increase
• Lack of additional insider purchases provides no affirmative signal of management confidence

Insights

Securities Analyst

TL;DR: Minor, non-discretionary insider sale; neutral impact.

The 875-share disposition represents less than 3% of Patrick Lamy’s existing position and was executed solely to cover payroll taxes tied to RSU vesting. Because the trade was mandated under Akero’s pre-arranged sell-to-cover program, it offers little incremental insight into management’s outlook. Lamy’s remaining 31,698-share stake shows continued alignment, and no derivative positions were reported. For investors, this filing is routine and should not affect valuation or sentiment.

Corporate Governance Specialist

TL;DR: Governance-compliant sell-to-cover, negligible governance signal.

The filing confirms adherence to Section 16 reporting requirements and Akero’s Rule 10b5-1 compliant tax-withholding program. Automatic execution mitigates concerns about opportunistic trading. Insider ownership remains substantial, maintaining governance alignment. Overall, the event is ordinary-course and carries no material governance red flags.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lamy Patrick

(Last) (First) (Middle)

C/O AKERO THERAPEUTICS, INC.

601 GATEWAY BLVD, SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, Commercial Strategy

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/20/2025		S(1)		875	D	$54.59	31,698	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Jonathan Young, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Akero Therapeutics (AKRO) shares did Patrick Lamy sell?

He sold 875 shares of common stock.

What was the sale price reported in the Form 4?

The shares were sold at $54.59 per share.

Why were the shares sold by the insider?

The sale was a sell-to-cover transaction to pay tax withholdings on vested RSUs.

How many AKRO shares does Patrick Lamy still own after the transaction?

He directly owns 31,698 shares following the sale.

Were any derivative securities involved in this filing?

No, no derivative securities were acquired or disposed of.